Telluride Medical Partners Accepted Into Johnson & Johnson’s JLABS Program

AAEAAQAAAAAAAAq2AAAAJDhiYTdjZWNiLWFlNTEtNDNhMy04MWZhLWZkMzUzNzUxZmI2ZA.jpg

Telluride Medical Partners announced today that the company has been accepted as a member of Johnson & Johnson’s JLABS program and will be a resident company at the prestigious Texas Medical Center located in Houston, TX.

“We are thrilled to be part of an elite program dedicated to innovation and providing essential resources for startup medical device companies,” says Eric Wells, Founder & CEO of Telluride Medical Partners.

Providing a capital efficient and flexible platform, the JLABS program focuses on supporting emerging medical device, pharmaceutical, consumer and digital health companies through the tenuous time between early discovery to moving a product through the path to commercialization. 

“The JLABS program will provide our team access to core research facilities, capital providers, educational programs, operational capabilities and a community of like-minded entrepreneurs, all critical to advancing our early-stage med tech companies,” says Wells.

Beyond their growing network of incubation capabilities around the world, JLABS is part of the larger Johnson & Johnson Innovation family of companies including Johnson & Johnson Innovation centers, housing their deal teams and therapeutic experts for early-stage development, Johnson & Johnson Innovation – JJDC, Inc., their established venture capital arm, and Johnson & Johnson Innovation – BD, their business development group focusing on later-stage development. 

In addition being a strategic partner with Johnson & Johnson through the JLABS program, Telluride Medical Partners will also be a resident company at the Texas Medical Center, the largest medical complex in the world.

“At the forefront of advancing life sciences, the Texas Medical Center is home to the world’s largest cancer center and sees over 8 million patient visits per year. Having a presence at the Texas Medical Center will provide a concentrated set of unmatched clinical use, marketing and commercialization opportunities to Telluride Medical Partners,” says Wells.  

Telluride Medical Partners Joins AdvaMed

0d45e3f.png

Telluride Medical Partners is pleased to announce that it is a member of the Advanced Medical Technology Association (AdvaMed), a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. 

“We are thrilled to be a part of this elite group that acts as the common voice for companies producing medical devices, diagnostic products and health information systems,” says Eric Wells, CEO of Telluride Medical Partners. “As a company advancing innovative medical device technologies, it is an honor to be a part of this group that advocates on a global basis for the highest ethical standards, timely patient access to safe and effective products, and economic policies that reward value creation,” states Wells.

AdvaMed promotes competitive policies that foster the highest ethical standards, rapid product approvals, appropriate reimbursement, and access to international markets. To learn more about AdvaMed visit www.advamed.org.

Telluride Medical Partners Presents Lighthill Medical at the Texas Life Science Forum

Texas-Life-Science-Forum.png
IMG_1471.JPG

On Tuesday, November 7, Telluride Medical Partners presented one of their portfolio companies, Lighthill Medical, at the must-attend Texas Life Science Forum in Houston, TX.

“The Texas Life Science Forum is a premier life science event in Texas,” says Eric Wells, CEO of Telluride Medical Partners. “As a presenting company, this was a great opportunity for Telluride Medical Partners to further expose Lighthill Medical to potential investors, science companies, entrepreneurs, investment professionals, big pharma as well as business executives in the life science industry,” says Wells.

Lighthill Medical, managed by Telluride Medical Partners, is developing a family of catheters for the delivery of oncology agents for image-guided, minimally invasive interventional procedures. The Lighthill Medical family of catheters utilizes a proprietary, all-in-one form factor, along with temporary occlusion, to significantly reduce the time and costs associated with targeted cancer treatments while maintaining clinical safety and efficacy.

To learn more about Lighthill Medical and investment opportunities, click here.

Nectero Medical Closes $1 Million Bridge Round Over-Subscribed

Nectero Logo.png

Nectero Medical, Inc., a Telluride Medical Partners portfolio company, announced today that it has closed $1 million of convertible notes as part of a bridge financing following its acquisition of Vatrix Medical, Inc. on April 28, 2017.

“This is great news for Nectero Medical and its stakeholders”, states Eric Wells, CEO of Telluride Medical Partners. “This new capital will allow Nectero Medical to take its patented technology that combats abdominal aortic aneurysms (AAA) to the next commercial milestone, further de-risking the investment for strategic partners, adding value to the company for investors, and providing hope for a new clinical treatment to patients living with AAA,” says Wells.

The convertible note financing, originally offered at $750,000, drew strong interest from investors based on the disruptive technology and promising early-stage in-vivo test results. The company was able to close the round over-subscribed by 33% and secured key, strategic relationships with investors in both Germany and China.

Nectero Medical has developed a technology that prevents and treats vascular aneurysms, a fatal disease that causes the walls of blood vessels to expand, weaken, and ultimately rupture. Currently, the sole treatment for such aneurysms is surgical intervention, and only five percent of patients are candidates for this high-risk procedure. Nectero Medical’s minimally invasive treatment, AAvert, is targeting the unmet need of watchful, waiting and contra-indicted patients, worth $6B today.

Capture Vascular Continues with New Clinical Cases for its MegaVac Mechanical Thrombectomy System

Capture Vascular, Inc. (Capture) recently completed three successful clinical cases using its proprietary MegaVacTM Mechanical Thrombectomy System-ATK.
 
The first case involved a 42-year-old male patient with a target treatment area of the right leg, above and below the knee. Overall the MegaVacTM Mechanical Thrombectomy System was noted that it worked both easy and well and the procedure was marked successful.
 
The second case involved a 62-year-old female patient with a target treatment area of the left leg above the knee. Again the system was noted as working both easy and well where the procedure was not only successful, but the MegaVacTM Mechanical Thrombectomy System exceeded expectations.
 
The third case involved a 67-year-old male patient with a target treatment area of the left leg, above and below the knee. The MegaVacTM Catheter and ThromboWireTM Clot Retractor both performed well with debris noted in the ThromboWireTM Clot Retractor after removal.
 
Capture will continue to perform clinical cases throughout the coming months as it focuses on adoption of the MegaVacTM Mechanical Thrombectomy System-ATK.
 
The recently expanded device description of the ATK builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel, in addition to being able to pass through other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System-ATK can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“In working through recent clinical experiences we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customer’s needs and execute these device advances,” says Wells.
 
Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. 

--

About Capture Vascular, Inc.
Headquartered in Telluride, Colorado, Capture Vascular, Inc. is a Medical Device development company that was founded in May of 2013 to pursue the development and commercialization of innovative medical devices. Capture Vascular’s platform technology is the MegaVacTM Mechanical Thrombectomy System that offers several unique features in one simple, efficient, and effective device. Capture Vascular, Inc. is managed by Telluride Medical Partners LLC. For more information about Capture Vascular and its technology please visit www.capturevascular.com.

Dr. Richard Fulton Steps Down as Chief Medical Officer

Dr. Richard Fulton announced today that he is stepping down from his role as Chief Medical Officer at Telluride Medical Partners.

An esteemed medical practitioner who practiced radiology and interventional radiology for 30 years prior to joining TMP, Dr. Fulton is a prolific inventor with 50-plus issued patents as well as a number of successfully commercialized medical devices including Capture Vascular’s MegaVac Mechanical Thrombectomy System. He has dedicated his post practice life to inventing novel, easy-to-use, and cost-effective devices and products designed to address a wide-range of medical conditions and treatment dilemmas.

“We are grateful to have had Dr. Fulton as part of the TMP team and respect his decision to spend more time with his family”, states Eric Wells, CEO of TMP.

Dr. Fulton will continue to sit on the board for both Capture Vascular and Awestruck Dental, two companies he founded over the last half decade. A true idea-man and passionate inventor, Dr. Fulton will also continue to work on new medical devices outside of TMP.

“We wish Dr. Fulton all of the best of luck with his future endeavors and we thank him for his time serving as Chief Medical Officer at Telluride Medical Partners,” says Wells.

Capture Vascular, Inc. Secures Updated FDA 510(k) Clearance

Capture Vascular Inc. (Capture), a Telluride Medical Partners company, announced today that it has received updated FDA 510(k) clearance that expands the device description for its proprietary MegaVacTM Mechanical Thrombectomy System.

“In working through recent clinical experiences, we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customers needs and execute these device advances,” says Wells.

The expanded device description builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel and being able to pass other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“We are confident that Vascular Surgeons, Interventional Cardiologists and Interventional Radiologists will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive peripheral treatments,” says Wells.

Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. For more information about Capture Vascular and its technology please visit www.capturevascular.com.

AngelMD Features Capture Vascular In Startup Spotlight Blog

AngelMD, an equity crowdfunding company that connects physician investors with leading medical startups, featured Capture Vascular as a featured startup company on the angelMD blog.

“The mechanical thrombectomy market is ready for a new technology to replace outdated methods. Devices currently in the market have been used for over a decade and fall short as they are prone to distal embolization, inefficient aspiration, and clogging…”

Read the full spotlight here.

Telluride Venture Accelerator Innovation Showcase

Photo Credit: Telluride Venture Accelerator

Photo Credit: Telluride Venture Accelerator

On July 18, 2017 Telluride Medical Partners was a featured company at the Telluride Venture Accelerator's Innovation Showcase event. The event highlighted up-and-coming companies headquartered in Telluride, CO and was a great opportunity to further expose TMP, its companies, its team, and its technologies to potential investors. Over 50 people attended the event and we received a lot of interest in TMP and its companies.

Medical Device Entrepreneur Robert Whirley Joins Telluride Medical Partners Board of Advisors

Telluride Medical Partners (TMP) is pleased to announce that longtime medical device industry expert and entrepreneur Robert Whirley has joined the TMP Board of Advisors.

“We could not be more thrilled to have Robert Whirley, a medical device leader with 20 years of in-depth medical experience to be part of our Board of Advisors team,” stated Eric Wells, Founder and Chief Executive Officer of TMP.

A longtime medical device consultant, Whirley has worked for successful healthcare companies such as Boston Scientific and TriVascular, Inc., and has demonstrated a proven ability to build teams and take products from concept to global commercialization.

“Whirley has worked with leading biotech medical clients to address key challenges in product development, global regulatory compliance, strategic planning and fundraising for medical device and biotech clients ranging from early-stage ventures to established public companies,” Wells says. “He has strong engineering and communication skills with a thorough understanding of U.S. and European clinical trial and regulatory approval processes, the latter of which will be especially valuable when we take our medical devices and technologies abroad.”

In addition, Whirley has extensive experience in product development, approval strategy, aligning physician inputs with product definition and device durability, and is also the inventor/co-inventor of over 20 issued patents and published applications.